# Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

> **NCT07087223** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 42 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer NSCLC

## Interventions

- **DRUG:** Vebreltinib combined with Furmonertinib
- **DRUG:** Vebreltinib combined with Furmonertinib
- **DRUG:** Vebreltinib combined with Furmonertinib

## Key facts

- **NCT ID:** NCT07087223
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07087223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07087223, "Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07087223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*